Abstract: Objective To explore the predictive value of glycemic variability on the recent major cardiovascular adverse events in acute coronary syndrom patients. Methods From July 2016 to March 2018, a total of two hundred and forty-seven ACS patients in hospital were included. According to the 30-day follow-up whether occuring MACE, patients were classsfied into MACE group （n=28） and non-MACE group （n=219）, the general clinical data, biochemistry and ultrasonic and glycemic variability indexes were compared between two groups, the independent risk factors of MACE during 30-day follow-up of ACS patients were analyzed by using Logistic regression analysis. The predictive value of glycemic variability on MACE was assessed by using ROC curve. Meanwhile, the survival analysis were implemented by using Kaplan-Meier. Results The triple-vessel disease, GRACE scores on admission in the MACE group were significantly higher than in the non-MACE group （P<0.05）. Compared to the non-MACE group, the levels of LVEDD, fasting blood glucose, BNP, CRP, blood glucose standard deviation （BGSD）, mean amplitude of glycemic excursion （MAGE） were increased and LVEF were decreased in the MACE group, the differences between the two groups were statistically significant （all P<0.05）. Logistic regression analysis showed that triple-vessel disease, GRACE scores, BNP, CRP, BGSD, MAGE were independent risk factors for MACE in ACS patients during 30-day follow-up （all P<0.05）. The ROC curve analysis showed that BGSD predicted MACE with AUC was 0.883 （95CI: 0.836~0.920, P<0.000 1）, the cut-off value were 2.07 mmol/L, which yield sensitivity and specificity were 82.1% and 79.5%, respectively. The cumulative risk of MACE during 30-day follow-up increased markedly who over the cut-off value of glycemic variability （P<0.05）. Conclusion There is closely correlation between glycemic variability and recent major cardiovascular adverse events in acute coronary syndrom patients, its can be used as a factor for the poor prognosis of patients.

Key words: Acute coronary syndrom, Glycemic variability, Major cardiovascular adverse events, Prognosis